MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317867 | Name: Fenoldopam mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fenoldopam mesylate is a synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is used as an antihypertensive agent. It was approved by the Food and Drug Administration (FDA) in September 1997. Since fenoldopam is the only intravenous agent that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant renal insufficiency.

Chemical Structure

Fenoldopam mesylate
Fenoldopam mesylate
CAS#67227-57-0 (mesylate)

Theoretical Analysis

MedKoo Cat#: 317867

Name: Fenoldopam mesylate

CAS#: 67227-57-0 (mesylate)

Chemical Formula: C17H20ClNO6S

Exact Mass: 0.0000

Molecular Weight: 401.86

Elemental Analysis: C, 50.81; H, 5.02; Cl, 8.82; N, 3.49; O, 23.89; S, 7.98

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
67287-54-1 (HBr) 181217-39-0 (HCl) 67227-57-0 (mesylate)
Synonym
Fenoldopam mesylate; Corlopam; Fenoldopam methanesulfonate; SKF 82526J; SKF-82526J; SKF82526J
IUPAC/Chemical Name
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol; methanesulfonate
InChi Key
CVKUMNRCIJMVAR-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16ClNO3.CH4O3S/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;1-5(2,3)4/h1-4,7,13,18-21H,5-6,8H2;1H3,(H,2,3,4)
SMILES Code
OC1=CC=C(C2CNCCC3=C2C=C(C(O)=C3Cl)O)C=C1.CS(=O)(O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 401.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Naeem M, McEnteggart GE, Murphy TP, Prince E, Ahn S, Soares G. Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis. Clin Imaging. 2015 Sep-Oct;39(5):759-64. doi: 10.1016/j.clinimag.2015.02.003. Epub 2015 Feb 12. Review. PubMed PMID: 25709111. 2: Caixeta A, Dogan O, Weisz G. Contrast-induced nephropathy: protective role of fenoldopam. Clin Exp Pharmacol Physiol. 2012 Jun;39(6):497-505. doi: 10.1111/j.1440-1681.2012.05707.x. Review. PubMed PMID: 22642656. 3: Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, Calabrò MG, Sheiban I, Tumlin JA, Ranucci M, Zangrillo A. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2008 Feb;22(1):27-33. doi: 10.1053/j.jvca.2007.07.015. Epub 2007 Nov 7. Review. PubMed PMID: 18249327. 4: Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, Ranucci M, Zangrillo A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007 Jan;49(1):56-68. Review. PubMed PMID: 17185146. 5: Walker PD, Brokering KL, Theobald JC. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy. 2003 Dec;23(12):1617-26. Review. PubMed PMID: 14695041. 6: Thompson EJ, King SL. Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity. Crit Care Nurse. 2003 Jun;23(3):39-46. Review. PubMed PMID: 12830779. 7: Mathur VS. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med. 2003;4 Suppl 1:S35-40. Review. PubMed PMID: 12556736. 8: Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Rev Cardiovasc Med. 2003;4 Suppl 1:S15-20. Review. PubMed PMID: 12556733. 9: Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med. 2001;2 Suppl 1:S4-8. Review. PubMed PMID: 12439361. 10: Vijayakumar E. New drugs: fenoldopam mesylate, glycoprotein IIb/IIIa antagonists, and K+ATP-channel agonists. Int Anesthesiol Clin. 2002 Winter;40(1):35-60. Review. PubMed PMID: 11910249. 11: Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001 Nov 22;345(21):1548-57. Review. PubMed PMID: 11794223. 12: Shorten GD. [Fenoldopam: potential clinical applications in heart surgery]. Rev Esp Anestesiol Reanim. 2001 Dec;48(10):487-91. Review. Spanish. PubMed PMID: 11792308. 13: Chu VL, Cheng JW. Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother. 2001 Oct;35(10):1278-82. Review. Erratum in: Ann Pharmacother 2002 Feb;36(2):346. Ann Pharmacother 2001 Dec;35(12):1677. PubMed PMID: 11675860. 14: Strauser LM, Pruitt RD, Tobias JD. Initial experience with fenoldopam in children. Am J Ther. 1999 Sep;6(5):283-8. Review. PubMed PMID: 11329109. 15: Oparil S, Aronson S, Deeb GM, Epstein M, Levy JH, Luther RR, Prielipp R, Taylor A. Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens. 1999 Jul;12(7):653-64. Review. PubMed PMID: 10411362. 16: Post JB 4th, Frishman WH. Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies. J Clin Pharmacol. 1998 Jan;38(1):2-13. Review. PubMed PMID: 9597553. 17: Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs. 1997 Oct;54(4):634-50. Review. PubMed PMID: 9339965. 18: Nichols AJ, Ruffolo RR Jr, Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990 Jun;3(6 Pt 2):116S-119S. Review. PubMed PMID: 1974439. 19: Holcslaw TL, Beck TR. Clinical experience with intravenous fenoldopam. Am J Hypertens. 1990 Jun;3(6 Pt 2):120S-125S. Review. PubMed PMID: 1974440.

View History

NDM-1 inhibitor-2

NDM-1 inhibitor-2